Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Nov 09, 2018 11:02am
84 Views
Post# 28950332

RE:RE:RE:Some interesting UK HIV data

RE:RE:RE:Some interesting UK HIV data
Wino115 wrote: One other fact about Europe is that something like half the HIV cases get identified in "late stages", where it's harder to control than if identified early.  I don't know if this is more eastern Europe focused or not.  I would guess it is as I believe Russia may even be included in those WHO numbers.  But those UK numbers would back up Europe roughly doubling the market size for Trogarzo as the company has indicated.


This was my first look at find Europe data and facts, it seems well documented in the UK. The xls data in the second link is helpful as well

I also found some useful UK resistance surveillance data here. Resistance levels have dropped but seem to have stabalized in recent years.

https://www.ctu.mrc.ac.uk/hivrdb/public/surveillance.asp

Bullboard Posts